Table 2.
Description of characteristics and reported outcomes of randomized registration clinical trials of alfuzosin.
| Study (author) | Study type | Duration (weeks) | Treatment (daily dose) | Patients (n) | Change in symptoms (IPSS) (%) | Change in Qmax (mL/s) | PVR change (%) | Adverse events (%) | LE |
|---|---|---|---|---|---|---|---|---|---|
| Jardin et al.26 | RCT | 24 | Placebo | 267 | −32 | +1.3 | −9 | 9.0 | 1b |
| Alfuzosin 3 × 2.5 mg | 251 | −42 | +1.4 | −39 | 10.8 | ||||
| Buzelin et al.27 | RCT | 12 | Placebo | 196 | −18 | +1.1 | 0 | 7.1 | 1b |
| Alfuzosin 2 × 5 mg | 194 | −31 | +2.4 | −17 | 4.6 | ||||
| van Kerrebroeck, et al.28 | RCT | 12 | Placebo | 154 | −27.7 | +1.4 | /// | 1b | |
| Alfuzosin 3 × 2.5 mg | 150 | −38.1 | +3.2 | 9.4 | |||||
| Alfuzosin 1 × 10 mg | 143 | −39.9 | +2.3 | 6.3 |
LE: level of evidence; PVR: post-voided residual; RCT: randomized clinical trial.